Plus Therapeutics Inc (PSTV)
1.360
+0.01
(+0.75%)
USD |
NASDAQ |
Nov 04, 16:00
1.33
-0.03
(-2.21%)
After-Hours: 20:00
Plus Therapeutics Research and Development Expense (TTM): 10.82M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 10.82M |
| March 31, 2024 | 9.47M |
| December 31, 2023 | 9.69M |
| September 30, 2023 | 9.034M |
| June 30, 2023 | 9.486M |
| March 31, 2023 | 10.90M |
| December 31, 2022 | 9.699M |
| September 30, 2022 | 9.41M |
| June 30, 2022 | 7.956M |
| March 31, 2022 | 6.231M |
| December 31, 2021 | 5.573M |
| September 30, 2021 | 4.82M |
| June 30, 2021 | 3.665M |
| March 31, 2021 | 3.667M |
| December 31, 2020 | 3.481M |
| September 30, 2020 | 4.114M |
| June 30, 2020 | 4.699M |
| March 31, 2020 | 4.88M |
| December 31, 2019 | 5.365M |
| September 30, 2019 | 5.272M |
| June 30, 2019 | 5.577M |
| March 31, 2019 | 6.239M |
| December 31, 2018 | 7.312M |
| September 30, 2018 | 8.07M |
| June 30, 2018 | 9.848M |
| Date | Value |
|---|---|
| March 31, 2018 | 10.89M |
| December 31, 2017 | 13.36M |
| September 30, 2017 | 13.83M |
| June 30, 2017 | 14.79M |
| March 31, 2017 | 17.04M |
| December 31, 2016 | 16.20M |
| September 30, 2016 | 17.97M |
| June 30, 2016 | 18.36M |
| March 31, 2016 | 19.16M |
| December 31, 2015 | 19.00M |
| September 30, 2015 | 17.36M |
| June 30, 2015 | 16.15M |
| March 31, 2015 | 14.78M |
| December 31, 2014 | 15.10M |
| September 30, 2014 | 17.18M |
| June 30, 2014 | 18.16M |
| March 31, 2014 | 17.64M |
| December 31, 2013 | 17.07M |
| September 30, 2013 | 16.01M |
| June 30, 2013 | 15.44M |
| March 31, 2013 | 14.51M |
| December 31, 2012 | 13.63M |
| September 30, 2012 | 11.57M |
| June 30, 2012 | 10.85M |
| March 31, 2012 | 10.69M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
3.481M
Minimum
Dec 2020
10.90M
Maximum
Mar 2023
6.998M
Average
6.231M
Median
Mar 2022
Research and Development Expense (TTM) Benchmarks
| Perspective Therapeutics Inc | 28.53M |
| Retractable Technologies Inc | 0.654M |
| InfuSystems Holdings Inc | -- |
| Xtant Medical Holdings Inc | 2.145M |
| Catheter Precision Inc | 0.219M |